During the past decade, Atlanta Urological Group conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Atlanta Urological Group" #1 collaborator was "Foundation Medicine" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Atlanta Urological Group" are "Metastatic Castration Resistant Prostate Cancer" (2 trials). Many other conditions were trialed in "Atlanta Urological Group" in a lesser frequency.

Most popular intervention types in "Atlanta Urological Group" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Rucaparib" (2 trials) and "Abiraterone acetate or Enzalutamide or Docetaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Atlanta Urological Group" are 2 trials for "Male" genders.

Currently, there are NaN active trials in "Atlanta Urological Group". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Atlanta Urological Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Atlanta Urological Group, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".